OPKO Health
OPK
$1.60
Share price
0.00%
Change (1 day)
17.65%
Change (1 year)
P/S ratio for OPKO Health (OPK)
P/S ratio as of December 2023 (TTM): 1.43
According to OPKO Health 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.4266. At the end of 2023 the company had a P/S ratio of 1.43.
P/S ratio history for OPKO Health from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 1.43 | 48.33% |
| 2022 | 0.9618 | -47.92% |
| 2021 | 1.85 | 0.15% |
| 2020 | 1.84 | 68.89% |
| 2019 | 1.09 | -38.74% |
| 2018 | 1.78 | -30.6% |
| 2017 | 2.57 | -39.5% |
| 2016 | 4.24 | -61.9% |
| 2015 | 11.1 | -76.5% |
| 2014 | 47.4 | 31.4% |
| 2013 | 36.1 | 15.46% |
| 2012 | 31.2 | -31.05% |
| 2011 | 45.3 | 78.27% |
| 2010 | 25.4 | -28.04% |
| 2009 | 35.3 | 3.57% |
| 2008 | 34.1 | |
| 2003 | 58.6 | 824.51% |
| 2002 | 6.34 | -84.32% |
| 2001 | 40.4 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 4.10 | 187.14% | 🇺🇸 USA |
 Abbott Laboratories ABT | 4.52 | 216.88% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 7.06 | 395.14% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.27 | 59.21% | 🇺🇸 USA |
 LabCorp LH | 1.36 | -4.36% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | 12.9 | 804.67% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 0.7412 | -48.05% | 🇮🇱 Israel |
 Ardelyx ARDX | 9.16 | 542.30% | 🇺🇸 USA |